Cited by CrossRef (43)
- Kelly Q. Zhou, Simerdeep K. Dhillon, Laura Bennet, Alistair J. Gunn, Joanne O. Davidson. Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy—Is Exendin-4 the Answer?. IJMS 2022;23:10191

- LongQing Zhang, Wen Zhang, XueBi Tian. The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases. International Journal of Neuroscience 2023;133:473

- Bruno Vergès, Victor Aboyans, Denis Angoulvant, Pierre Boutouyrie, Bertrand Cariou, Fabien Hyafil, Kamel Mohammedi, Pierre Amarenco. Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. Cardiovasc Diabetol 2022;21

- Jinjing Wei, Bing Yang, Ruxin Wang, Haowen Ye, Ying Wang, Lihong Wang, Xiaofang Zhang. Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis. Front. Endocrinol. 2022;13

- Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi. Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions. Biomedicines 2024;12:1630

- Matteo Apicella, Maria Cristina Campopiano, Michele Mantuano, Laura Mazoni, Stefano Del Prato. Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete. L'Endocrinologo 2020;21:241

- Е. L. Nasonov, Т. S. Panevin, Е. А. Troshina. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. Naučno-praktičeskaâ revmatologiâ 2024;62:135

- Jing Huang, Xin-Shang Wang, Tian Gao, Xing Wang, Man-Yang Yu, Hao-Xin Song, Bi-Yan Wang, Ling-Mei Li, Qiang Zeng, Hui-Nan Zhang. Astrocyte KDM4A mediates chemokines and drives neutrophil infiltration to aggravate cerebral ischemia and reperfusion injury. J Cereb Blood Flow Metab 2024;44:491

- Luiza P. Géa, Eduarda D. da Rosa, Bruna S. Panizzutti, Érica Z. de Aguiar, Larissa F. de Oliveira, Pamela Ferrari, Angelo Piato, Rosane Gomez, Rafael Colombo, Adriane R. Rosa. Reduction of hippocampal IL-6 levels in LPS-injected rats following acute exendin-4 treatment. Naunyn-Schmiedeberg's Arch Pharmacol 2020;393:1303

- Diego Incontri Abraham, Melissa Gonzales, Antonio Ibarra, Cesar V. Borlongan. Stand alone or join forces? Stem cell therapy for stroke. Expert Opinion on Biological Therapy 2019;19:25

- Shan-Shan Cui, Xiao-Bo Feng, Bing-Hong Zhang, Zhong-Yuan Xia, Li-Ying Zhan. Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation. Neural Regen Res 2020;15:1333

- Eridan Rocha-Ferreira, Laura Poupon, Aura Zelco, Anna-Lena Leverin, Syam Nair, Andrea Jonsdotter, Ylva Carlsson, Claire Thornton, Henrik Hagberg, Ahad A Rahim. Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy. 2018;141:2925

- Mark P Maskery, Christian Holscher, Stephanie P Jones, Christopher I Price, W David Strain, Caroline L Watkins, David J Werring, Hedley CA Emsley. Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. J Cereb Blood Flow Metab 2021;41:14

- Xinwang Yang, Ying Wang, Chunyun Wu, Eng-Ang Ling. Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders. CMC 2019;26:4749

- Minji Sohn, Juan P. Frias, Soo Lim. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials. Diabetes Obesity Metabolism 2023;25:3560

- Aditi Shankar, Aditi Sharma, Chirag Buch, Robert J. Chilton. The evolving role of GLP-1 agonists in ischemic stroke prevention in diabetic patients. 2024;13

- Dimitrios Milonas, Triantafyllos Didangelos, Apostolos I. Hatzitolios, Konstantinos Tziomalos. Incretin-Based Antihyperglycemic Agents for the Management of Acute Ischemic Stroke in Patients with Diabetes Mellitus: A Review. Diabetes Ther 2019;10:429

- Chang Ho Ahn, Soo Lim. Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. J Stroke 2019;21:139

- Chenqi Lu, Cong Xu, Jun Yang. The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties. Medicina 2024;61:17

- Eleni Xourgia, Eleni-Margarita Tzouganatou, Athanasia Papazafiropoulou, Andreas Melidonis. Anti-inflammatory properties of antidiabetic agents. WJMA 2019;7:129

- Soo Lim, Tae Jung Oh, Jesse Dawson, Naveed Sattar. Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obesity Metabolism 2020;22:6

- Jing Sun, Suzhi Liu, Zongxin Ling, Fangyan Wang, Yi Ling, Tianyu Gong, Na Fang, Shiqing Ye, Jue Si, Jiaming Liu. Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota. J. Agric. Food Chem. 2019;67:3006

- Tram Thi Ngoc Nguyen, Hojung Choi, Hee-Sook Jun. Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression. Front. Pharmacol. 2020;11

- Kathryn K. Ridout, Shariful A. Syed, Hung-Teh Kao, Barbara Porton, Anna V. Rozenboym, Jean Tang, Sasha Fulton, Tarique Perera, Andrea P. Jackowski, John G. Kral, Audrey R. Tyrka, Jeremy Coplan. Relationships Between Telomere Length, Plasma Glucagon-like Peptide 1, and Insulin in Early-Life Stress–Exposed Nonhuman Primates. Biological Psychiatry Global Open Science 2022;2:54

- Xiaoyan Yang, Peng Feng, Rong Ji, Yiqing Ren, Wenshi Wei, Christian Hölscher. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease. Expert Opinion on Therapeutic Targets 2022;26:445

- Maria Shvedova, Yana Anfinogenova, Elena N. Atochina-Vasserman, Igor A. Schepetkin, Dmitriy N. Atochin. c-Jun N-Terminal Kinases (JNKs) in Myocardial and Cerebral Ischemia/Reperfusion Injury. Front. Pharmacol. 2018;9

- Xiaoyan Yang, Qiang Qiang, Nan Li, Peng Feng, Wenshi Wei, Christian Hölscher. Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research. Front. Neurol. 2022;13

- Ziyu Wang, Xiaolu Zhang, Guangming Zhang, Yu Jia Zheng, Anliu Zhao, Xijuan Jiang, Jiali Gan. Astrocyte modulation in cerebral ischemia-reperfusion injury: A promising therapeutic strategy. Experimental Neurology 2024;378:114814

- Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies. Type 2 diabetes. The Lancet 2022;400:1803

- Bandy Chen, Xiaofei Yu, Claudia Horvath-Diano, María José Ortuño, Matthias H. Tschöp, Ania M. Jastreboff, Marc Schneeberger. GLP-1 programs the neurovascular landscape. Cell Metabolism 2024;36:2173

- Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, Durga Lohana, Parkash Kumar, Savitri Aninditha Nandula, Fatima Kausar Nawaz, Kevin Tracey, Huan Yang, Derek LeRoith, Michael J. Brownstein, Jesse Roth. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front. Immunol. 2023;14

- Francesco Bifari, Roberto Manfrini, Michele Dei Cas, Cesare Berra, Matteo Siano, Massimo Zuin, Rita Paroni, Franco Folli. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research 2018;137:219

- Jian Xu, Guihong Wei, Jingjing Wang, Jiali Zhu, Min Yu, Xiaoning Zeng, Hong Wang, Weiping Xie, Hui Kong. Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function. Laboratory Investigation 2019;99:577

- Amra Jujic, João P. P. Vieira, Hana Matuskova, Peter M. Nilsson, Ulf Lindblad, Michael H. Olsen, João M. N. Duarte, Anja Meissner, Martin Magnusson. Plasma Galectin-4 Levels Are Increased after Stroke in Mice and Humans. IJMS 2023;24:10064

- Damla Erbil, Candan Yasemin Eren, Cağrı Demirel, Mehmet Utku Küçüker, Ihsan Solaroğlu, Hale Yapıcı Eser. GLP-1’s role in neuroprotection: a systematic review. Brain Injury 2019;33:734

- Emőke Horváth, Adina Huțanu, Liviu Chiriac, Minodora Dobreanu, Alex Orădan, Előd-Ernő Nagy. Ischemic damage and early inflammatory infiltration are different in the core and penumbra lesions of rat brain after transient focal cerebral ischemia. Journal of Neuroimmunology 2018;324:35

- Łukasz Bułdak, Grzegorz Machnik, Estera Skudrzyk, Aleksandra Bołdys, Bogusław Okopień. The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Exp Ther Med 2019

- Arashdeep Singh, Rizaldy C. Zapata, Adel Pezeshki, Matthew L. Workentine, Prasanth K. Chelikani. Host genetics and diet composition interact to modulate gut microbiota and predisposition to metabolic syndrome in spontaneously hypertensive stroke‐prone rats. FASEB j. 2019;33:6748

- Ingrid Lovise Augestad, Doortje Dekens, Dimitra Karampatsi, Osama Elabi, Alexander Zabala, Hiranya Pintana, Martin Larsson, Thomas Nyström, Gesine Paul, Vladimer Darsalia, Cesare Patrone. Normalisation of glucose metabolism by exendin‐4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. British J Pharmacology 2022;179:677

- Xian-kun Tu, Ping-ping Chen, Jing-yi Chen, Yi-hang Ding, Quan Chen, Song-sheng Shi. GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation. Neuropharmacology 2023;237:109603

- Yan Chen, Ying-na Xu, Chen-yu Ye, Wen-bo Feng, Qing-tong Zhou, De-hua Yang, Ming-wei Wang. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1156

- C. Meurot, C. Jacques, C. Martin, L. Sudre, J. Breton, R. Rattenbach, K. Bismuth, F. Berenbaum. Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?. Journal of Orthopaedic Translation 2022;32:121

- Daniella C Terenzi, Ehab Bakbak, Hwee Teoh, Aishwarya Krishnaraj, Pankaj Puar, Ori D Rotstein, Francesco Cosentino, Ronald M Goldenberg, Subodh Verma, David A Hess. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity. 2024;119:2858
